Takeda Entered into an Exclusive License Agreement with Puma Biotechnology for the Development and Commercialization of Alisertib
Shots:
- Takeda to receive a $7M up front license fee & is also eligible to receive an additional fee of ~$287.3M upon achievement of regulatory and commercial milestones along with royalty on net sales of alisertib
- Puma will be responsible for the development & commercialization of alisertib globally. The initial focus is the development of alisertib for the treatment of metastatic ER+ HER2- breast cancer, TNBC, and SCLC
- Additionally, the therapy showed clinical activity in ER+ breast cancer patients prior treated with a CDK4/6 inhibitor & also provides benefits to breast cancers patients who have developed resistance to other treatments modalities
Ref: Businesswire | Image: Takeda
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
